Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group.

Karampeazis A, Vamvakas L, Kentepozidis N, Polyzos A, Chandrinos V, Rigas G, Christofyllakis C, Kotsakis A, Hatzidaki D, Pallis AG, Georgoulias V.

Clin Lung Cancer. 2016 Nov;17(6):543-549. doi: 10.1016/j.cllc.2016.05.009. Epub 2016 Jun 2.

PMID:
27397849
2.

Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).

Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A.

Clin Transl Oncol. 2017 Mar;19(3):317-325. doi: 10.1007/s12094-016-1532-y. Epub 2016 Aug 4.

PMID:
27492015
3.

Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study.

Karampeazis A, Vamvakas L, Kotsakis A, Christophyllakis C, Kentepozidis N, Chandrinos V, Agelidou A, Polyzos A, Tsiafaki X, Hatzidaki D, Georgoulias V.

J Geriatr Oncol. 2017 Jan;8(1):23-30. doi: 10.1016/j.jgo.2016.05.002. Epub 2016 Jun 2.

PMID:
27264267
4.

A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.

Kontopodis E, Kotsakis A, Kentepozidis N, Syrigos K, Ziras N, Moutsos M, Filippa G, Mala A, Vamvakas L, Mavroudis D, Georgoulias V, Agelaki S.

Cancer Chemother Pharmacol. 2016 May;77(5):949-56. doi: 10.1007/s00280-016-2997-7. Epub 2016 Mar 19.

PMID:
26994909
5.

Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI.

Nikolaou C, Matikas A, Papavasilopoulou M, Mavroudis D, Vamvakas L.

Case Rep Oncol Med. 2015;2015:659624. doi: 10.1155/2015/659624. Epub 2015 May 21.

6.

Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).

Katsaounis P, Kotsakis A, Agelaki S, Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou A, Karachaliou N, Hatzidaki D, Georgoulias V.

Cancer Chemother Pharmacol. 2015 Apr;75(4):821-7. doi: 10.1007/s00280-015-2707-x. Epub 2015 Feb 22.

PMID:
25702051
7.

Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).

Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, Mavroudis D, Georgoulias V.

Lung Cancer. 2015 Apr;88(1):57-62. doi: 10.1016/j.lungcan.2015.01.012. Epub 2015 Jan 23.

PMID:
25662596
8.

Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.

Kontopodis E, Kentepozidis N, Christophyllakis Ch, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas L, Agelaki S, Kotsakis A, Vardakis N, Georgoulias V, Mavroudis D.

Cancer Chemother Pharmacol. 2015 Jan;75(1):153-60. doi: 10.1007/s00280-014-2628-0. Epub 2014 Nov 15.

PMID:
25398698
9.

Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG).

Vamvakas L, Matikas A, Karampeazis A, Hatzidaki D, Kakolyris S, Christophylakis C, Boukovinas I, Polyzos A, Georgoulias V, Souglakos J.

BMC Cancer. 2014 Apr 22;14:277. doi: 10.1186/1471-2407-14-277.

10.

Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥ 70 years).

Basso U, Roma A, Brunello A, Falci C, Fiduccia P, Banzato A, Bononi A, Gusella M, Vamvakas L, Zagonel V, Monfardini S.

J Geriatr Oncol. 2013 Oct;4(4):340-5. doi: 10.1016/j.jgo.2013.07.004. Epub 2013 Aug 15.

PMID:
24472477
11.

Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.

Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, Kotsakis A, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, Mavroudis D, Georgoulias V.

Cancer. 2013 Aug 1;119(15):2754-64. doi: 10.1002/cncr.28132. Epub 2013 May 9.

12.

Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.

Kentepozidis N, Kotsakis A, Soultati A, Agelaki S, Christophylakis Ch, Agelidou M, Chelis L, Papakotoulas P, Vamvakas L, Zafiriou Z, Samonis G, Georgoulias V.

Cancer Chemother Pharmacol. 2013 Mar;71(3):605-12. doi: 10.1007/s00280-012-2037-1. Epub 2013 Jan 22.

PMID:
23338050
13.

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.

Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, Mavroudis D, Georgoulias V, Souglakos J.

Br J Cancer. 2012 Dec 4;107(12):1932-7. doi: 10.1038/bjc.2012.509. Epub 2012 Nov 20.

14.

Colovesical fistula demonstrated on renal cortical scintigraphy.

Stathaki M, Vamvakas L, Papadaki E, Papadimitraki E, Tsaroucha A, Karkavitsas N.

Clin Nucl Med. 2012 Nov;37(11):1112-4. doi: 10.1097/RLU.0b013e31826c0d27.

PMID:
23047758
15.

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).

Souglakos J, Ziras N, Kakolyris S, Boukovinas I, Kentepozidis N, Makrantonakis P, Xynogalos S, Christophyllakis Ch, Kouroussis Ch, Vamvakas L, Georgoulias V, Polyzos A.

Br J Cancer. 2012 Jan 31;106(3):453-9. doi: 10.1038/bjc.2011.594. Epub 2012 Jan 12.

16.

A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.

Pallis AG, Voutsina A, Kentepozidis N, Giassas S, Papakotoulas P, Agelaki S, Tryfonidis K, Kotsakis A, Vamvakas L, Vardakis N, Georgoulias V.

Clin Lung Cancer. 2012 Mar;13(2):129-35. doi: 10.1016/j.cllc.2011.08.004. Epub 2011 Oct 14.

PMID:
22000696
17.

Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study.

Karampeazis A, Vamvakas L, Agelidou A, Kentepozidis N, Chainis K, Chandrinos V, Vardakis N, Pallis AG, Christophyllakis C, Georgoulias V.

Clin Lung Cancer. 2011 May;12(3):155-60. doi: 10.1016/j.cllc.2011.03.015. Epub 2011 Apr 27.

PMID:
21663857
18.

A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.

Saridaki Z, Malamos N, Kourakos P, Polyzos A, Ardavanis A, Androulakis N, Kalbakis K, Vamvakas L, Georgoulias V, Mavroudis D.

Cancer Chemother Pharmacol. 2012 Jan;69(1):35-42. doi: 10.1007/s00280-011-1663-3. Epub 2011 May 18.

PMID:
21590447
19.

Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.

Pallis AG, Syrigos K, Kotsakis A, Karachaliou N, Polyzos A, Chandrinos V, Varthalitis I, Christophyllakis C, Ardavanis A, Vamvakas L, Vardakis N, Saridaki Z, Samonis G, Giassas S, Georgoulias V, Agelaki S.

Clin Lung Cancer. 2011 Mar;12(2):100-5. doi: 10.1016/j.cllc.2011.03.004. Epub 2011 Apr 11.

PMID:
21550556
20.

Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group.

Pallis AG, Karampeazis A, Vamvakas L, Vardakis N, Kotsakis A, Bozionelou V, Kalykaki A, Hatzidaki D, Mavroudis D, Georgoulias V.

Ann Oncol. 2011 Nov;22(11):2448-55. doi: 10.1093/annonc/mdq772. Epub 2011 Mar 10.

PMID:
21393380

Supplemental Content

Loading ...
Support Center